Literature DB >> 2417421

[Operative therapy of cancer of the head of the pancreas--determination of surgical status].

H G Beger, R Bittner.   

Abstract

Therapy of ductal pancreatic carcinoma still remains a hardly resolved problem. In spite of the development of highly sensitive diagnostic methods 85 to 90% of the patients do not undergo therapy until they have already reached an incurable tumor stage. 5 years survival rate between 4 and 8% after potentially curative resections are rather depressing numbers. To patients with stages I and II duodenopancreatectomy as performed as subtotal pancreatectomy promises better mean survival and 5 years survival rates than bypass procedures only. When the tumor, however, infiltrates adjacent organs, resection might be limited to few selected cases. Substantial progress in the therapy of pancreatic carcinoma can be only expected from better understanding of the biological nature of the tumor, from earlier diagnosis and more precise selection of the patients as to the appropriate therapeutical alternatives.

Entities:  

Mesh:

Year:  1985        PMID: 2417421

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  2 in total

1.  The role of anti-p53-autoantibodies in pancreatic disorders.

Authors:  S Gansauge; F Gansauge; G Negri; P Galle; J Müller; A K Nüssler; B Poch; H G Beger
Journal:  Int J Pancreatol       Date:  1996-06

2.  Studies of pancreatic cancer utilizing monoclonal antibodies.

Authors:  M Büchler; H Friess; P Malfertheiner; K H Schultheiss; K H Muhrer; H P Kraemer; H G Beger
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.